(Boursier.com) — Innate Pharma fell 0.4% to 2.25 euros this Wednesday, after having published its turnover and its cash position for the first 9 months of the year 2023. As of September 30, 2023, cash, cash equivalents and financial assets of the company amounted to 121.9 million euros. As of the same date, the company’s total financial liabilities amounted to €40.3 million.
Revenue for the first 9 months of 2023 amounted to 36.5 million euros, compared to 44.3 million euros for the first 9 months of 2022.
For the 9-month period ending September 30, 2023, revenue mainly comes from the partial or full recognition of payments received under collaboration and licensing agreements with AstraZeneca, Sanofi and Takeda.
Among the latest broker opinions, Goldman Sachs has adjusted the cursor on the file from 2.75 to 2.50 euros while remaining ‘neutral’.
©2023 Boursier.com